TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04143958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agalsidase beta (GZ419828)
Description: Pharmaceutical form:Powder for concentrate for solution for infusion Route of administration: Intravenous (IV) infusion,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: agalsidase alfa
Description: Pharmaceutical form:concentrate for solution for infusion Route of administration: Intravenous (IV) infusion
Study: NCT04078386

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 240 mg
Description: Arm Description:Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 160 mg
Description: Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
Study: NCT03351803

Intervention type: OTHER
Intervention: BFOR Digital Health solution/Web Portal
Description: A digital health solution with Internet-based participant recruitment and ascertainment is a mechanism for distributing access to genetic testing to populations who might not otherwise have access. For this project, LifeLink will build a private web-portal designed by the PI's of the study as described in this protocol, including the wireframes that are in the appendices, that will enable secure contact between study participants and the participating commercial laboratory (Quest Diagnostics) and BFOR researchers, as well as facilitate contacts between study participants and their primary care providers and/or a list of BFOR study centers and BFOR providers.
Study: NCT00600522

Intervention type: PROCEDURE
Intervention: Ultrasound-guided hepatectomy
Description: After laparotomy and staging by intraoperative ultrasound (IOUS), anterior surface of the hepatocaval confluence is exposed. Than, compression by means of the surgeon's finger-tip is applied at the MHV caval confluence verifying at color-Doppler IOUS the disappearance of the blood flow in the MHV or its inversion. Then, MHV clamping itself is carried out, and parenchymal sparing resection would be selected if at least one of these 3 findings is confirmed:~1. Reversal color-Doppler IOUS flow direction in the peripheral portion of the MHV, which suggests the drainage through collateral circulation in the RHV/LHV depending on the side of the MHV branch with reversal flow.~2. Detectable shunting collaterals at color-Doppler IOUS with RHV or LHV.~3. Hepatopetal flow in P5-8 and/or P4inf portal branches. If none of these finding is confirmed and in particular hepatofugal flow direction in the P5-8 and/or P4 inf is detected the hepatectomy has to be extended.
Study: NCT00501631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VIVITROL 380 mg
Description: Administered via IM injection once every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VIVITROL 380 mg
Description: Administered via IM injection once every 4 weeks.
Study: NCT01994200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Team-Based Approach
Description: Three meetings will be scheduled with the oncology dedicated-nurse. First meeting: information about the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; as well as surgery and its' short- and long-term consequences. Second meeting: information on radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations. Third meeting: how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities. The dedicated nurse, in collaboration with the Department of Nursing and ENT, will develop and implement an interdisciplinary team-based approached developed for this study according to guidelines of the Programme québécois de lutte contre le cancer (PQLC).

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Control
Description: Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
Study: NCT02837588

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperthermy treatment with MJS electrode
Description: 30 patients who are diagnosed Pelvic pain with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
Study: NCT00902863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YOGA
Description: Patients with chronic pain will undergo a six week course of YOGA
Study: NCT03085303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full Body Blue Light Device
Description: Full body blue light irradiation (phototherapy) of atopic dermatitis patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full Body Blue Light Device
Description: Full body blue light irradiation (phototherapy) of atopic dermatitis patients.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Full Body Blue Light Device
Description: Full body blue light irradiation (phototherapy) of atopic dermatitis patients.
Study: NCT03448848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCAA preparation Intravenous infusion
Description: BCAA IVi in a dose 0.5-1 gm/Kg/day for 2-5 days post liver surgery versus sterile normal saline in a volume equal to the study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile normal saline
Description: sterile normal saline in a volume equal to the study drug
Study: NCT06436716

Intervention type: RADIATION
Intervention: MRI
Description: Every patient needs an MRI to assess spinal cord injury. This is one of the clinically necessary examinations.

Intervention type: RADIATION
Intervention: MRI
Description: Every patient needs an MRI to assess spinal cord injury. This is one of the clinically necessary examinations.

Intervention type: RADIATION
Intervention: MRI
Description: Every patient needs an MRI to assess spinal cord injury. This is one of the clinically necessary examinations.

Intervention type: RADIATION
Intervention: MRI
Description: Every patient needs an MRI to assess spinal cord injury. This is one of the clinically necessary examinations.
Study: NCT01082419

Intervention type: DEVICE
Group type: OTHER
Intervention: ARFI measurement
Description: ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For group A the measurement is made by a second and a third investigator during the same examination.

Intervention type: DEVICE
Group type: OTHER
Intervention: ARFI measurement
Description: ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For all other groups (B, C, D, E) ARFI is measured only once.

Intervention type: DEVICE
Group type: OTHER
Intervention: ARFI measurement
Description: ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For all other groups (B, C, D, E) ARFI is measured only once.

Intervention type: DEVICE
Group type: OTHER
Intervention: ARFI measurement
Description: ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For all other groups (B, C, D, E) ARFI is measured only once.

Intervention type: DEVICE
Group type: OTHER
Intervention: ARFI measurement
Description: ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For all other groups (B, C, D, E) ARFI is measured only once.

Intervention type: DEVICE
Group type: OTHER
Intervention: ARFI measurement
Description: ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For groups F and G : ARFI is measured again after clinical healing.

Intervention type: DEVICE
Group type: OTHER
Intervention: ARFI measurement
Description: ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For groups F and G : ARFI is measured again after clinical healing.
Study: NCT02742207

Intervention type: OTHER
Intervention: Electrical atrial fibrillation Cardioversion
Description: Electrical cardioversion for patients admitted for Atrial Fibrillation

Intervention type: OTHER
Intervention: Cardioversion
Description: Electrical cardioversion for patients admitted for Atrial Fibrillation
Study: NCT03314480

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized physical examination
Description: Standarized physical examination dedicated to assess a potential fracture in the maxillofacial or mandibular region.

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized physical examination
Description: Standarized physical examination dedicated to assess a potential fracture in the maxillofacial or mandibular region.
Study: NCT01122173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Atrial fibrillation ablation procedure
Study: NCT00856180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT01426581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teach-To-Goal
Description: Participants observe a demonstration on the use of each inhaler, with corresponding verbal step-by-step instructions (demonstration, verbal instruction), then participants 'teachback or re-demonstrate the steps; cycles are repeated are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Participants are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)
Study: NCT03387293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGI-LII Breakfast
Description: This test meal with low GI and low FII amounts were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGI-LII Breakfast
Description: This test meal with low GI and low FII amounts were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGI-HII Breakfast
Description: In crossover design, this test meal with low GI and high FII amounts were served as a breakfast to compare the LGI-LII Breakfast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGI-HII Breakfast
Description: In crossover design, this test meal with low GI and high FII amounts were served as a breakfast to compare the LGI-LII Breakfast.
Study: NCT03225430

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural treatment for tics
Description: Mainly based on the habit reversal treatment (HRT) and in addition to HRT components, they learn awareness training, relaxation, competing response, contingency management, and generalization training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive psychophysiological
Description: Focus on the processes influencing thoughts and behaviors underlying tics.
Study: NCT03340883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BION-1301
Description: a solution for intravenous (IV) administration, diluted and administered Q2W
Study: NCT03527264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab induction
Description: 2 doses Nivolumab 240mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab induction
Description: 2 doses Nivolumab 240mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab induction
Description: 2 doses Nivolumab 240mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab induction
Description: 2 doses Nivolumab 240mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total dose of 45 Gy in 25 fractions at 180 cGy/fx~Whole pelvic or extended field

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total dose of 45 Gy in 25 fractions at 180 cGy/fx~Whole pelvic or extended field

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total dose of 45 Gy in 25 fractions at 180 cGy/fx~Whole pelvic or extended field

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total dose of 45 Gy in 25 fractions at 180 cGy/fx~Whole pelvic or extended field

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab with chemoradiation
Description: Nivolumab 240mg IV every 14 days (+/- 3 days) for 3 doses, administered concomitantly during chemoradiation and beginning day 1 of Radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab with chemoradiation
Description: Nivolumab 240mg IV every 14 days (+/- 3 days) for 3 doses, administered concomitantly during chemoradiation and beginning day 1 of Radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab with chemoradiation
Description: Nivolumab 240mg IV every 14 days (+/- 3 days) for 3 doses, administered concomitantly during chemoradiation and beginning day 1 of Radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab maintenance
Description: Nivolumab 480 mg IV every 4 weeks for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab maintenance
Description: Nivolumab 480 mg IV every 4 weeks for 2 years
Study: NCT00626639

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous (IV) bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifermin
Description: Administered by intravenous (IV) bolus injection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation \[one fraction per day\])

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation \[one fraction per day\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/m\^2 intravenously (IV) on days 1, 22 and 43.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m\^2 intravenously (IV) on days 1, 22 and 43.
Study: NCT00644059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted trivalent inactivated subunit influenza vaccine
Description: Either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine
Description: For both vaccines, either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
Description: 1. Meningococcal vaccine: two IM injections~2. Tick-borne encephalitis vaccine: two IM injections
Study: NCT03357757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 10 mg/kg IV
Study: NCT02101151

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3(cholecalciferol)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3(cholecalciferol)
Study: NCT02020941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV or PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01877798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: volume resuscitation, vasoactive drug

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: volume resuscitation, vasoactive drug
Study: NCT03599960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: * Idarubicin 12mg/m2 IV at D1~* Methotrexate at D1 (24H infusion, alkaline hydration, leucovorin rescue):~  * Patients \<65y and albuminemia \>35 g/l and CrCl (MDRD)\>60 ml/min: 3000 mg/m²~ * Patients \<65y and albuminemia \<35 g/l and/or CrCl (MDRD) \<60 ml/min: 1000 mg/m² IV~ * Patients ≥65y and albuminemia \>35 g/l and CrCl (MDRD) \> 60 ml/min : 1000 mg/m²~ * Patients ≥ 65y and albuminemia \< 35 g/l and/or CrCl (MDRD) \< 60 ml/min : 500 mg/m²~* L-asparaginase (SPECTRILA) : 5000 units/m² IV at D2, 5, 8, 11 (switch to Erwinia asparaginase/Cirsantaspase 25 000 U/m² with the same drug regimen in case of hypersensitivity reactions or significant diminution of asparaginase activity)~* Dexamethasone 40mg PO or IV at D1-4 (dose diminution at 20 mg for Age ≥65y)
Study: NCT00822848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: I.V., days 1-3 of each cycle. Epirubicin to be omitted during cycle 2 (concomitant chemoradiation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Over 90 minutes I.V., days 1-3 of each cycle. Administered with hydration and Mesna.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: P.O. daily beginning 2 weeks before first chemotherapy cycle, held 1 week before and after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Preoperative administration has been the preference at our institution.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Surgery should be planned for 2-4 weeks after the initiation of chemotherapy for cycle 3.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: 28 Gy (350 centigray (cGy) x 8 fractions in 10 days) beginning at the start of cycle 2. \*Boost: postoperative boost of 12 Gy (200 cGy x 6 fractions) for patients with positive surgical margins only.
Study: NCT03329989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: During 3 treatment visits 12 injections will be given per treatment area
Study: NCT03558516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium group
Description: We will dilute magnesium 6 gram with 0.9% sodium chloride to 30 ml. The patient will receive magnesium sulfate 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline group
Description: The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
Study: NCT02431429

Intervention type: DRUG
Intervention: Miltefosine
Study: NCT03424278

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor control exercises
Description: Motor control exercises for the deep trunk muscles in patients with chronic low back pain is based on evidence of motor control dysfunction, including delayed onset of activity in the transversus abdomens and internal oblique abdominal muscles and segmental hypertrophy of the lumbar multifidus muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training exercises
Description: A type of strength-building exercise program that requires the body muscle to exert a force against some form of resistance, such as weight, stretch bands, water, or immovable objects. Resistance exercise is a combination of static and dynamic contractions involving shortening and lengthening of skeletal muscles.
Study: NCT01492959

Intervention type: DRUG
Intervention: insulin human
Description: Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment
Study: NCT00620906

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Manipulation
Description: HVLA manipulation to Sacroiliac Joint
Study: NCT02054156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: 3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin solution for inhalation
Description: 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tobramycin solution for inhalation
Description: 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months